The 12th Annual Personalized Medicine Conference, NOVEMBER 15 – 17, 2016, Joseph B. Martin Conference Center, HARVARD MEDICAL SCHOOL, Boston
LPBI Group’s Announcement on REAL TIME Press Coverage – Pending
PROGRAM SUMMARY NOVEMBER 15
NOVEMBER 16
NOVEMBER 17
|
SOURCE
From: <cwells@personalizedmedicinecoalition.org>
Date: Tuesday, May 10, 2016 at 3:03 PM
To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>
Subject: Now Available: 12th Annual PM Conference Program
November 16
PROGRAM
Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115
7:00 a.m. — Registration and Continental Breakfast
8:00 a.m. — Opening Remarks
- Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
8:15 a.m. — The Personalized Medicine Report
- William S. Dalton, Ph.D., M.D., CEO, M2Gen, Chairman, Personalized Medicine Coalition
8:30 a.m. — Keynote Speaker
- Greg Simon, Executive Director, Cancer Moonshot Task Force
9:00 a.m. — Pioneering Precision: Charting a Course for Cutting-Edge Innovations
Many scientists believe innovations in personalized medicine are poised to yield major breakthroughs in coming years, but not all members of the health care system are clear on which research topics have the most potential. The participants in this panel will identify the most encouraging scientific directions for personalized medicine and point to the most promising topics for future research. Confirmed panelists include:
- Moderator: Stephen Eck, M.D., Ph.D., Vice President, Oncology Medical Sciences, Astellas Pharma Global Development
- Barbara Weber, M.D., Interim Chief Medical Officer, Neon Therapeutics
10:00 a.m. — Networking Break
10:30 a.m. — Money Talks: The Future of Investment in Personalized Medicine
Innovation requires investment. During this discussion, a panel of diverse investors will illuminate the most promising business opportunities for advancing personalized medicine, focusing on both macro and micro environments while also discussing the barriers to investment and potential solutions for removing them. Confirmed panelists include:
- Moderator: Edward Winnick, Editor in Chief, GenomeWeb
- Alexis Borisy, Partner, Third Rock Ventures
- Vamil Divan, M.D., M.B.A., Senior Research Analyst, Credit Suisse
- Ryan Lindquist, Director, Investment Banking, Leerink Partners
11:30 a.m. — Leadership in Personalized Medicine Award
- Presenter: William S. Dalton, Ph.D., M.D., CEO, M2Gen, Chairman, Personalized Medicine Coalition
- Recipient: TBD
12:00 p.m. — Luncheon
1:15 p.m. — “Precision Trials Challenge” Award
A question-and-answer session with the winner of Harvard Business School’s “Precision Trials Challenge.”
1:45 p.m. — Reforming Clinical Trials: How Alternative Trial Designs May Reshape Regulatory Review
Traditional clinical trial designs are often too cumbersome and expensive to study the efficacy of personalized medicine products and services in sub-populations of patients. Yet there is no consensus on which methods have the most promise to speed trials and lower costs. During this session we will explore which of the latest progressive designs are best suited to demonstrate the efficacy of personalized medicine based on past successes and proposed reforms.
- Invited: Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
2:15 p.m. — Keynote Speaker
- Peer M. Schatz, M.B.A., CEO, Qiagen
2:45 p.m. — Networking Break
3:15 p.m. — Diagnostics Debate: Regulatory and Reimbursement Hurdles for Personalized Medicine Diagnostics
Nowhere are the regulatory and reimbursement challenges facing personalized medicine more evident than in the diagnostics industry, where the routes to market are often hampered by a lack of clarity regarding the possible changes to the regulatory pathway for laboratory-developed tests, ambiguity regarding the kinds of evidence that justify payment, and the need for large marketing budgets to sell low-cost procedures, all of which impede the development of sophisticated diagnostics with the power to transform medicine.
During this panel discussion, representatives from a diverse range of diagnostics companies and a payer will identify the most promising strategies to alter the landscape to encourage the investment in personalized medicine diagnostic products, including the roles of other stakeholders such as the pharmaceutical industry and integrated health systems. Confirmed panelists include:
- Suzanne Belinson, Ph.D., M.P.H., Executive Director, Center for Clinical Effectiveness, Blue Cross Blue Shield Association
- Brad Gray, CEO, Nanostring
- L. Patrick James, M.D., Chief Clinical Officer, Health Plans and Policy, Medical Affairs, Quest Diagnostics
- Michael Pellini, M.D., CEO, Foundation Medicine
4:30 p.m. — Visions of Value: Evaluating Evidence for Personalized Medicine
The fact that payers, providers, patients, industry representatives and regulators all define value differently makes it difficult for personalized medicine’s champions to contribute to and communicate about the body of evidence supporting the field. Participants in this panel discussion will bring the personalized medicine community closer to an accepted definition of value by identifying common elements in multiple stakeholders’ understanding of the concept. Confirmed panelists include:
- Peter Bach, M.D., Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
- Donna Cryer, J.D., President and CEO, Global Liver Institute
- Michael Kolodziej, M.D., National Medical Director, Oncology Solutions, Aetna
- Lori Reilly, J.D., Executive Vice President, Policy & Research, PhRMA
5:30 p.m. — Elements Café Cocktail Reception
#PMConf
– See more at: http://www.personalizedmedicinecoalition.org/Conference/November_16_Program#sthash.82P77U2y.dpuf
November 17
PROGRAM
Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115
7:00 a.m. — Registration and Continental Breakfast
8:00 a.m. — Opening Remarks
- Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
8:15 a.m. — Keynote Speaker
- Daniel O’Day, COO, Pharmaceuticals Division, Roche
8:45 a.m. — Coverage is King: Identifying the Evidence That Leads to Reimbursement
Many innovators in personalized medicine are unclear on the kinds of evidence that inform the coverage and payment decisions of payers. That lack of clarity can have negative financial consequences for personalized medicine companies with products and services that are on the market but not paid for. During this panel, payer representatives will help define the reimbursement landscape for the field by providing examples of the evidence they consider appropriate for coverage and payment. Confirmed panelists include:
- Moderator: Amy M. Miller, Ph.D., Executive Vice President, Personalized Medicine Coalition
- Kristine Bordenave, M.D., Lead Medical Director, Humana
- Matthew Fontana, M.D., Vice President and Chief Medical Officer, Pharmacy, Health Care Service Corporation
- Elaine Jeter, M.D., MolDx Medical Director, Palmetto GBA
9:45 a.m. — Networking Break
10:15 a.m. — Harvard Business School Case Study Presentation
DNA-editing technologies have been hailed as revolutionary with the possibility to edit out mutations that cause disease. Yet the CRISPR-Cas system is currently locked in a legal dispute between two great research institutions involving, as one journalist put it, “who own molecular biology.” The CRISPR technology in short raises the broader issue of whether these new techniques should be privately owned or placed in the public domain. The technology also raises serious ethical issues. The case study will serve as the point of departure for our discussion of these issues.
- Richard Hamermesh, D.B.A., Senior Fellow and Former MBA Class of 1961, Professor of Management Practice, Harvard Business School
11:15 a.m. — Keynote Speaker
- Victor Dzau, M.D., President, National Academy of Medicine
11:45 a.m. — Bag Lunch
12:45 p.m. — Personalizing Care: Strategies for Integrating Personalized Medicine into Health Care
Personalized medicine lacks sufficient literature on how health care providers can integrate personalized medicine into clinical care, which makes it difficult for providers to take advantage of the growing number of personalized medicine products and services now available to them. During this session, panelists who have spearheaded integration efforts will share the strategies they found most useful for speeding the pace of personalized medicine’s adoption in clinical settings. Confirmed panelists include:
- Moderator: Howard McLeod, Pharm.D., Medical Director, DeBartolo Family Personalized Medicine Institute, Moffitt Cancer Center
- Amy Abernethy, M.D., Ph.D., Chief Medical Officer & Senior Vice President, Oncology, Flatiron Health
- Lincoln Nadauld, M.D., Ph.D., Director, Cancer Genomics, Intermountain Healthcare
1:45 p.m. — You + 999,999: How a 1 Million-Person Cohort Can Pave the Way for Personalized Care
- Invited: Eric Dishman, Director, Precision Medicine Initiative Cohort Program, National Institutes of Health
2:15 p.m. — Networking Break
2:45 p.m. — The Data Dilemma: Defining Information’s Role in the Future of Personalized Medicine
Many innovators believe future advancements in personalized medicine research will be informed by the vast amounts of data that personalized medicine companies and government agencies are now collecting, but the community has not come to a consensus on if, when and how those data can or should be used for research purposes. During this discussion, a panel of academic and industry experts will discuss positions on the circumstances, if any, under which they believe it is appropriate to use these data for research, including issues of data sharing and liquidity. Confirmed panelists include:
- Kris Joshi, Ph.D., Executive Vice President, Products, Change Healthcare
3:45 p.m. — Keynote Speaker: The Future of Personalized Medicine — Gene Editing, “Wearables,” Digital Health
- Anthony Philippakis, M.D., Ph.D., Chief Data Officer, Broad Institute and Partner, Google Ventures
4:30 p.m. — Closing Remarks
- Edward Abrahams, Ph.D., President, Personalized Medicine Coalition
#PMConf
– See more at: http://www.personalizedmedicinecoalition.org/Conference/November_17_Program#sthash.WznaJ322.dpuf
Leave a Reply